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[57] ABSTRACT
The present invention comprises a water-soluble





wherein X is a monovalvent cation, two of which are
present, selected from the group consisting of cyclo-
propanecarboxylato, shikimato, saccharatolactone,
galacturonato and N,N-dimethyglycinato; wherein Y is
a divalent cation selected from the group consisting of
citraconato, -1,1-cyclobutanedicarboxylato, 1,1-cyclo-
propanedicarboxylato, isocitratolactone and Z-
iminodiacetato where Z is boundto the nitrogen andis
ethyl, propyl, Isopropyl, n-butyl, sec-butyl, ter-butyl,
n-amyl, isoamyl or OH.
In one preferred aspect the water-soluble square-planar
cis-platinum(I]) four-coordinate complex has the. for-
mula:
trans-R,R-DACHPt({II) X2
wherein X is a monovalent cation. Two X substituents
are present in the platinum complex. These X substitu-
ents are preferably selected from the group consisting of
cyclopropanecarboxylato, shikimato, saccharatolac-
tone, galacturonato and N,N-dimethylglycinato. Both
X substituents are usuallyidentical butmay bedifferent.





BACKGROUND OF THE INVENTION
This invention relates to newly synthesized platinum
complexes. Theuse of these complexes in anti-tumor
chemotherapy is also described.
Cis-platinum (CDDP)is a highly effective drug in the
treatment of several neoplastic diseases in humans (Lo-
ehreret al. (1984) Ann. Int. Med. -V 100, pp 704-713).
However, its use is limited by severe systemic toxicity,
particularly nephrotoxicity and neurotoxicity (Zwelling
_et al. Platinum Complexes. In: Pharmacologic princi-
ples of cancer treatment (1982) Ed by B. A. Chabner,
Saunders, Philadelphia, Penn.). In an'attempt to modify
the therapeutic index of CDDP, new derivatives have
been synthesized during the last decade. However, the
development of some promising analogues has. been
prevented by their low hydrosolubility, which may
decrease their potential for clinical use (Burchenal et al.
(1979) Cancer Treat. Rep. V 63, pp 1493-1497).
In U.S. Pat.No. 4,256,652 are described certain plati-
num compounds comprising resolved stereoisomers of
1,2 diaminocyclohexane (DACH). The isomers utilized
were cis-DACH, trans-RR-DACH and trans-SS-
DACH. The platinum compounds described therein
contained,in addition to a resolved DACHisomer, two
hydrophilic platinum ligands such as bromide, iodide,
nitrate, bromoacetate, sulfate or glucuronate. The plati-
num compounds comprising the trans-RR-DACH were
described as often more therapeutically effective than
those bearing cis-DACH.
In European Patent Application number 184107104.6
(public. no. 0130482, Brown et al., published Jan. 1,
1985) many platinum complexes are described. The
platinum complexes described therein _comprised












These complexes comprised DACH ofan undefined
stereochemical structure and, in contrast to the com-
plexes of the present invention, was presumably a race-
mic mixtureofall possible DACH stereoisomers. These
complexes are further distinguished from those of the
' present invention byvirtue of their carboxylato ligands,
_analogous in somecases but different.
Featured advantages of the compoundsofthe present
invention include:
(1) High antitumoractivity;









(iii) Lack of cross-resistance in in vitro antitumorcell .










wherein X is a monovalent cation, two of which are
present, selected from the group consisting of cyclo-
propanecarboxylato, shikimato, saccharatolactone,
galacturonato and N,N-dimethylglycinato; wherein Yis
‘a divalent cation selected from the group consisting of
citraconato, 1,1-cyclobutanedicarboxylato, 1,1-cyclo-
propanedicarboxylato, isocitratolactone and Z-
iminodiacetato where Z is bound to the nitrogen andis
ethyl, propyl, isopropyl, n-butyl, sec-butyl, ter-butyl,
n-amyl, isoamyl or OH.
In one preferred aspect the water-soluble square-pla-
nar cis-platinum(II) four-coordinate complex has the
formula:
trans-R,R-DACHPt({II) X2
wherein X is a monovalent cation. Two X substituents
are present.in the platinum complex. These X substitu-
ents are preferably selected from the group consisting of
cyclopropanecarboxylato, shikimato, saccharatolac-
tone, galacturonato and N,N-dimethylglycinato. Both
X substituents are usually identical but may bedifferent.
When the water-soluble square-planar cis-platinum-
(11) four-coordinate complex has the formula:
trans-R,R-DACHPt(II Y
the Y substituent is preferably a single divalent cation
selected from the group consisting of citraconato, 1,1-
cyclobutanedicarboxylato, 1,1-cyclopropanedicarbox-
ylato, isocitratolactone and Z-iminodiacetato where Z
is. bound to the nitrogen andis ethyl, propyl, isopropyl,
n-butyl, sec-butyl, ter-butyl, n-amyl, isoamyl or OH.
In a most preferred embodiment the water-soluble
square-planar cis-platinum(I]) four-coordinate complex
having the formula:
trans-R,R-DACH Pt(H) Y
wherein Y is Z-iminodiacetato where Z is ethyl, propyl,
isopropyl, n-butyl, sec-butyl, ter-butyl, n-amyl, isoamyl
or OH.
In an important aspect the complexes of the present
invention demonstrate marked utility in a process for
treating animals having tumors sensitive to these com-
plexes. This process comprises administering to said
animals a pharmaceutical composition consisting essen-
tially of an therapeutically anti-tumor effective amount
of the water-soluble square-planar cis-platinum(II) four-
coordinate complex described above. For this process a
pharmaceutical composition comprising a platinum
complex of the present invention may be utilized. This
pharmaceutical composition is preferably in a unit dos-
age form suitable for administration to an animal af-
flicted with tumor cells. The unit dosage comprises a
therapeutically anti-tumor effective amount of the
5,011,959
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water-soluble square-planar cis-platinum(II) four-coor-
dinate complex. The therapeutically anti-tumor effec-
tive amount should usually be between 1 mg/kg and 20
mg/kg but may vary considerably based upon tumor
type and the judgementofthe attending therapist. Like-
wise the dosage frequency and duration are variable.
DESCRIPTION OF THE PREFERRED
EMBODIMENT
Cisplatin is an important anticancer drug whichhas
the potential to produce life-threatening nephrotoxicity.
While new platinum antitumor drugs have been pro-
duced which are relatively free from the potential to
producerenal injury, many experience significant water
solubility problems. The present invention comprises
several diaminocyclohexane platinum (DACH-Pt)anti-
tumor complexes which:(1) retain or surpass the antitu-
morefficacy ofcisplatin, (2) are non-cross resistant with
cisplatin in a murine leukemia cell line which is specifi-
cally resistant to this drug (L1210/cisplatin), (3) are
non-nephrotoxic and (4) are water soluble. These com-
pounds offer distinct advantages as antitumor agents
over the use of cisplatin. Table 1 lists the complexes of
the present invention.
TABLE1























































These examples are presented to described preferred
embodimentsand utilities of the present invention and
are not meantto limit the present invention unless oth-
erwise stated in the claims appended hereto.
EXAMPLE1
Cis-bis-dichioro(trans-R,R-DACH)platinum(D
To an aqueousfiltered solution of 16.6 g K2PtCl,
(0.04 mole in 250 ml of water) 4.56 g (8.4 mmole) of
trans-R,R-DACHwasadded. Thereaction mixture was
stirred at room temperature for 6-8 hours. A yellow
solid was precipitated, filtered, washed with water,
methanol and finally with acetone. The final product















in an analogous manner using stoichiometric amounts





R,R-, trans-S,S- or cis isomer], (1.0 g; 2.6 mmole) was
suspended ion water (20 ml), and a solution of Ag2SO4
(0.75 g; 2.4 mmole) in water (150 ml) was added. The
reaction mixture wasstirred at room temperature for 24
hours in the dark. The precipitated AgCl wasfiltered
off, and the yellow filtrate was evaporated to dryness at
45°-50° C. under reduced pressure using a rotary evap-






Sulfato (trans-R,R-DACH)platinum(II) H20 (0.423
g) was dissolved in water (25 ml) and an aqueoussolu-
tion of barium ethyliminodiacetate (0.332 g) was added
thereto. The reaction mixture was stirred for 30 minutes
at room temperature. BaSO, precipitate was filtered and
filtrate was evaporated to dryness at 40°-45° C. under
reduced pressure using a rotary evaporator. A cream-
colored solid was obtained which was finally purified
from n-propanol. The product was dried over P2Osin
vacuo.
Yield: 56%
The analytical data for the product are set forth in




N-ter butyliminodiacetato and N-hydrox-
yliminodiacetato were prepared in an analogous manner
to the above-mentioned method using stoichiometric
amounts (cal mmole) sulfato (trans-R,R-DACH)-




Sulfato(trans-R,R-DACH)platinum(I]) H20 (0.423 g)
was dissolved in water (20 ml) and solution of barium
citraconate preparedin situ (citraconic acid (0.13 g) and
Ba(OH)2 8H2 O (0.3 g) in H2O) was added thereto. The
reaction mixture was stirred for 30 minutes at room
temperature. Barium sulfate precipitate was filtered and
the filtrate was evaporated to dryness at 40°-45° C.
under reduced pressure using a rotary evaporator. A
cream colored product was obtained which wasfurther
‘dried over P20s in vacuo.





Sulfato(trans-R,R-DACH)platinum(1]) H20 (0.423 g)
was dissolved in water (100 ml) and barium 1,1-
cyclobutanedicarboxylate prepared in situ [1,!-
cyclobutanedicarboxylic acid (0.13 g) and Ba(OH)2
5,011,959
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8H20 (0.3 g) in water (200 ml)] was added thereto. The
reaction mixture was stirred for 30 minutes at room
temperature. Barium sulfate was filtered and thefiltrate
was evaporated to dryness at 40°-45° C. under reduced
pressure using a rotary evaporator. Solid was obtained




DACH) platinum(I}) were prepared in an analogous
mannerto the above mentioned methodbutusing trans-
S,S-DACH and cis-DACHligands.






g) was dissolved in water (20 ml) and an aqueoussolu-
tion of barium cyclopropanecarboxylate prepared in
situ. The reaction. mixture was added thereto. The bar-
ium cyclopropanecarboxylic acid was prepared by mis-
ing 0.172 g cyclopropanecarboxylic acid and 0.3 g Ba
(OH)2. 8H20 in water, stirred for 30 minutes at room
temperature. Barium sulfate was removedbyfiltration
and filtrate was evaporated to dryness at 40°-45° C.
under reduced pressure using a rotary evaporator. A
cream colored solid was obtained which was purified
from methanol. Thefinal product was dried over P205
in vacuo.
1,1-Cyclopropanedicarboxylato(trans-R,R-DACH)-
platinum(I]) was prepared in an analogous manner to
this method using stoichiometric amounts of Ba-1,1-
cyclopropanedicarboxylate ligand.




Sulfato(trans-R,R-DACH)platinum(ID H20 (0.423 g)
was dissolved in water (20 ml) and a solution of barium
shikimate (0.483 g in 50'ml water) was added thereto.
The reaction mixture was stirred for 30 minutes at room
temperature. Barium sulfate precipitate was filtered off
andthe filtrate was evaporated to dryness at 40°-45° C.
under vacuum using arotary evaporator..:A cream col-
ored solid was obtained which was purified from water.





R,R-DACH)platinum(I) were prepared in an analo-
gous. manner to this method: using stoichiometric
amounts of barium salts of respective acids.





Compound % Observed % Calculated
No. Cc H N Cc H N
1 29.99 5.44 8.02 29.63 5.21 8.64
2 29.85 5.12 7.61 30.11 5.64 8.10
3 31.52 5.72 7.55 31.58 5.87 7.89
4 33.17 5.71 7.47 32.96 6.08 7.69













Compound % Observed % Calculated
No. Cc H N c H N
6 32:85 562 642 32.96 6.08 7.64
7 31.31 549 7.42 31.58 5.87 7.63
8 31.09 5.81 7.25 3054 6.04 7.63
9 23.77 438 7.76 2353 4.94 8.23
10 28.95. 455 621 29.0 4.39 6.15
lt 29.83. 480 5.74 301 4.81 5.85
12 29.44 449 519 29.56 4.92 5.74
13 30.13 432. 555 3013 4.81 5.55
14 28.98 451 603 29.00 4.61 6.15
15 28.30 3.98 5.25 28.85 4.00 5.61
16 33.30 530 566 33.79 5.23 5.63
17 36.03. 533 4.00 35.66 5.05 4.16
18 29.32 443 «3.69 29.00 4.15 3.75
19 29.34 5.07 3.66 29.53 4.65 3.83
20 30.96 626. 10.15 3060 6.20 10.20
EXAMPLE8
Thein vitro antitumoractivities of the complexes of the
invention
Wild-type L1210 leukemic cells were grown as a
suspension. culture in McCoy’s 5A medium supple-
mented with 10% horse serum, glutamine, streptomycin
and penicillin at 37° C., 95% relative humidity and 5%
CO2. Four mi of cell. suspension (105 cells/ml) were
added to culture tubes and the appropriate amount of
drug was added(to yield 0.01, 0.1, 1 or 10 ug/ml final
concentration) to the culture tubes. After 72 hours of
incubation, the cell concentration in control and experi-
mental cultures were determined with the aid of the
Coulter counter model ZBrand the percent of growth
inhibition calculated. Thein vitro cytotoxicities ofplati-































In vivo antitumoractivities of the complexes of the
invention
BDF; mice were inoculated intraperitoneally with
106 L1210 cells. About 24 hours after inoculation (day
1), the mice were injected intraperitoneally with vary-
ing doses of complexes of the present invention. Six
mice were used for each dosage level with an equal
5,011,959
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number of mice inoculated with 106 L1210 cells being
left untreated as controls. The results [% T/C=(sur-









. . Days of
animals)X 100] are set forth below. Long-term survival Compound Optimal Administra- Long-term
signify that animals werealive 30 days after tumorinoc- No. Dose (mg/kg) tion % T/C Survivors
ulation. These results are set forth in Table 4. 9 50 i 156 ~~
TABLE 4 25 1,5,9 265 _
10 25 _1,5,9 200 —_
IN VIVO ANTITUMOR ACTIVITIES li 50 1 147 _—
Days of 10 12.5 1,5,9 140 _
Compound Optimal Administra- Long-term 6.25 1-9 398 3/6
No. Dose (mg/kg) tion % T/C Survivors 12 12.5 1-9 120 —
r Bo BS
12.5 1,5,9 324 1/6 . 516 12.5 1,5,9 283 —
3.15 1-9 434 4/6
2 56 1 129 _ 15 17 25 1,5,9 184 _
3 12.5 1 147 _ 19 12.5 1,5,9 238 —
12.5 1,5,9 318 2/6
4 50 1 158 _-
25 1,5,9 227 2/6 EXAMPLE10
5 50 1 155 ~
12.5 1,5,9 324 1/6 20 Structural Formulas .
6 50 1 145 _-
12.5 1,5,9 150 _ Structural formulas for compounds of the present
7 6.25 1,5,9 282 2/6 invention described in Tables 1 and 2 and elsewhere
8 6.25 1,5,9 271 1/6 herein are shown in Table 5 (not including water of
hydration, which are notcritical).
TABLE5
STRUCTURAL FORMULAS OF THE WATER-SOLUBLE SQUARE-
PLANARCIS-PLATINUM FOUR-COORDINATE COMPLEXES






also described as trans-R,R-DACH Pt(IDY,
whereY is the divalent cation Z-iminoiacetato






also described as trans-R,R-DACH PrIDY
where Yis the divalent cation Z-iminodiacetato






















STRUCTURAL FORMULAS OF THE WATER-SOLUBLE SQUARE-
PLANAR CIS-PLATINUM FOUR-COORDINATE COMPLEXES




















also described as: compounds 1-8 but with Z
being hydroxy.
Citraconato(trans-R,R-DACH) Pt(IDH20
also described as trans-R,R-DACH PtdIDY
where Y is the divalent cation citraconato.
1,1-cyclobutanedicarboxylato(trans-R,R-DACH)
Pt(I1)14H20
also described as compound.10 but with Y being
the divalent cation 1,1 cyclobutanedicarboxylato.






































STRUCTURAL FORMULAS OF THE WATER-SOLUBLE SQUARE-
PLANARCIS-PLATINUM FOUR-COORDINATE COMPLEXES
OF THE PRESENT INVENTION
NAME STRUCTURE
Same as compound 11 but with (cis-DACH)
in place of (trans-R,R-DACH).
1,1-cyclopropanedicarboxylato(trans-R,R- Oo
DACH) Pt(IDH20 NH2 Il
also described as compound 10 but with Y







also described as compound 10 but with Y being






also described as trans-R,R-DACH Pr(iDX2









also described as compound 16 but with X being
the monovalent cation shikimato.
Cis-bis-saccharatolactone(trans-R,R-DACH)





also described as compound 16 but with X being







also described as compound 16 but with Z being






STRUCTURAL FORMULASOF THE WATER-SOLUBLE SQUARE-
PLANAR CIS-PLATINUM FOUR-COORDINATE COMPLEXES







also described as compound 16 but with X being
the monovalent cation N,N-dimethylglycinato.
Changes may be madein the elements and reagents or
in the steps or the sequence of steps of the methods
described herein without departing from the content
and scope of the invention as defined in the following
claims,
Whatis claimed is:
1. A water-soluble square-planar cis-platinum(II)




wherein X is a monovalent: cation, selected from the
groupconsisting of galacturonato and N,N-dimethyl-
glycinato; wherein Y is a divalent cation selected from
the group consisting of  citraconato, 1,1-
cyclobutanedicarboxylato, 1,1-cyclopropanedicarbox-
ylato, and Z-iminodiacetato where Z is bound to nitro-
gen andis ethyl, propyl, isopropyl, n-butyl, sec-butyl,
ter-butyl, n-amyl, isoamyl or OH.
2. A water-soluble square-planar cis-platinum(ID
four-coordinate complex having the formula:
trans-R,R-DACH Pt(ID X2
wherein X is a monovalent cation, selected from the
group consisting of galacturonato and N,N-dimethyl-
glycinato.
3. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH PID Y
wherein Y is a divalent cation selected from the group
consisting of citraconato, 1,1-cyclobutanedicarbox-
ylato, and Z-iminodiacetato where Z is bound to nitro-
' gen and is ethyl, propyl, isopropyl, n-butyl, sec-butyl,
ter-butyl, n-amyl, isoamyl or OH. 7
4. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(II) Y
' wherein Y is Z-iminodiacetato where Z is bound to the
nitrogen and is ethyl, propyl, isopropyl, n-butyl, sec-
butyl, ter-butyl, n-amyl, isoamyl or OH.
5. A pharmaceutical composition in unit dosage form
suitable for administration to an animal having a tumor
sensitive to a platinum complex ofclaim 1, the composi-














amount of a water-soluble square-planar cis-platinum-





wherein X is a monovalentcation, selected from the
group consisting of galacturonato and N,N-dimethyl-
glycinato; where Y is a divalent cation selected from the
group consisting of citraconato, 1,1-cyclopropanedicar-
boxylato, and Z-iminodiacetato where Z is bound to
nitrogen and is ethyl, propyl, isopropyl, n-butyl, sec-
butyl, ter-butyl, n-amyl, isoamyl or OH and a pharma-
ceutically acceptablecarrier therefor.
6. A pharmaceutical composition in unit dosage form
suitable for administration to an animal having a tumor
sensitive to a platinum complex ofclaim 2, the composi-
tion comprising a therapeutically anti-tumor effective
amount of a water-soluble square-planar cis-platinum-
(ID) four-coordinate complex having the formula:
trans-R,R-DACH Pt(II) X
wherein X is a monovalent cation, two of which are
present, selected from the group consisting of galac-
turonato and N,N-dimethylglycinato and a pharmaceu-
tically acceptable carrier therefor.
7. A pharmaceutical composition in unit dosage form
suitable for administration to an animal having a tumor
sensitive to'a platinum complex ofclaim 3, the composi-
tion comprising a therapeutically anti-tumor effective
amount of a water-soluble square-planar cis-platinum-
(Il) four-coordinate complex having the formula:
trans-R,R-DACH Pt(IlD Y
wherein Y is a divalent cation selected from the group
consisting of citraconato, 1,1-cyclobutanedicarbox-
ylato, and Z-iminodiacetato where Z is boundto nitro-
gen andis ethyl, propyl, isopropyl, n-butyl, sec-butyl,
ter-butyl, n-amyl, isoamyl or OH and a pharmaceuti-
cally acceptable carrier therefor.
8. A pharmaceutical composition in unit dosage form
suitable for administration to an animal having a tumor
sensitive to a platinum complex of claim 4, the composi-
tion comprising a therapeutically anti-tumor effective
amount of a water-soluble square-planarcis-platinum-




wherein Y is Z-iminodiacetato where Z is bound to the
nitrogen and is ethyl, propyl, isopropyl, n-butyl, sec-
butyl, ter-butyl, n-amyl, isoamyl or OH and a pharma-
ceutically acceptable carrier therefor.
9. A water-soluble square-planar cis-platinum(I])
four-coordinate complex having the formula:
trans-R,R-DACHPt(I) X2
wherein X is N,N-dimethylglycinato.
10. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(II) X2
wherein X is galacturonato. .
11. A water-soluble square-planar cis-platinum(i])
four-coordinate complex having the formula:
trans-R,R-DACH Px(II) Y
wherein Y is citraconato.
12. A water-soluble square-planar cis-platinum(I])
four-coordinate complex having the formula:
trans-R,R-DACH Pt(ID Y
wherein Y is 1,1-cyclobutanedicarboxylato.
13. A water-soluble square-planar cis-platinum(I])
four-coordinate complex having the formula:
trans-R,R-DACH Pt(il) Y
wherein Y is isocitratolactone.
14. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(ID Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen andis ethyl.
15. A water-soluble square-planar cis-platinum(1))
four-coordinate complex having the formula:
trans-R,R-DACH Pi(II) Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen andis propyl. ,
16. A water-soluble square-planar cis-platinum(ID














wherein Y is Z-iminodiacetato where Z is bound to
nitrogen and is isopropyl.
17. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(ID Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen and is n-butyl.
18. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACHPt(II) Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen andis sec-butyl.
19. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(ID Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen andis ter-butyl.
20. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(IJ) Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen and is n-amyl.
21. A water-soluble square-planar cis-platinum(D)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(IIl) Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen and is isoamyl.
22. A water-soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-R,R-DACH Pt(II) Y
wherein Y is Z-iminodiacetato where Z is bound to
nitrogen and is OH.
23. A water soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
cis-DACH Ptdl Y
wherein Y is 1,1-cyclobutanedicarboxylato.
24. A water soluble square-planar cis-platinum(II)
four-coordinate complex having the formula:
trans-S,S-DACH Pt(ID Y
wherein Y is 1,1-cyclobutanedicarboxylato.
* * * *x *
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